The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Preliminary results from arm D of the SEQUOIA study: zanubrutinib plus venetoclax in CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, presents findings from arm D of the SEQUOIA study (NCT03336333), which is investigating the combination of zanubrutinib with venetoclax in chronic lymphocytic leukemia (CLL). The study found that patients with high-risk del17p or TP53 mutations had an undetectable measurable residual disease (MRD) rate of 59% in the bone marrow, but longer follow-up is needed. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Consultancy: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Honoraria: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche.
